<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    jbm
   </journal-id>
   <journal-title-group>
    <journal-title>
     Journal of Biosciences and Medicines
    </journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2327-5081
   </issn>
   <issn publication-format="print">
    2327-509X
   </issn>
   <publisher>
    <publisher-name>
     Scientific Research Publishing
    </publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">
    10.4236/jbm.2025.133018
   </article-id>
   <article-id pub-id-type="publisher-id">
    jbm-141303
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Articles
     </subject>
    </subj-group>
    <subj-group subj-group-type="Discipline-v2">
     <subject>
      Biomedical 
     </subject>
     <subject>
       Life Sciences
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    Beyond the Tumor: Cutaneous Manifestations of Paraneoplastic Syndromes
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       David Fernando
      </surname>
      <given-names>
       Ortiz-Pérez
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref> 
     <xref ref-type="aff" rid="aff2"> 
      <sup>2</sup>
     </xref> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Juan Diego
      </surname>
      <given-names>
       Emiliani-Cortes
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref> 
     <xref ref-type="aff" rid="aff2"> 
      <sup>2</sup>
     </xref> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Karen Andrea
      </surname>
      <given-names>
       Sierra-Tapia
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Gerwin Rafael
      </surname>
      <given-names>
       Pérez-Palmett
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Daniela
      </surname>
      <given-names>
       Rojas-Villafañe
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Felipe Alejandro
      </surname>
      <given-names>
       Ilelaty-Urbano
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Natalia Sofia
      </surname>
      <given-names>
       Torres-Herrera
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Alberto
      </surname>
      <given-names>
       Manotas-Giraldo
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Juliana
      </surname>
      <given-names>
       Álvarez-Díaz
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Lauris Del Carmen
      </surname>
      <given-names>
       Campo-Camacho
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Víctor Andres
      </surname>
      <given-names>
       Arteta-Reyes
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Víctor Andres
      </surname>
      <given-names>
       Torrente-Ramírez
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Robin Luis
      </surname>
      <given-names>
       Petro-Noriega
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Gustavo Alberto Gutiérrez
      </surname>
      <given-names>
       Barros
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       María Victoria
      </surname>
      <given-names>
       Morales-Morales
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
   </contrib-group> 
   <aff id="aff1">
    <addr-line>
     aDepartment of Internal Medicine, Cartagena del Mar Medical Center, Cartagena, Colombia
    </addr-line> 
   </aff> 
   <aff id="aff2">
    <addr-line>
     aInternal Medicine Program, Universidad del Sinú, Cartagena, Colombia
    </addr-line> 
   </aff> 
   <aff id="aff3">
    <addr-line>
     aGeneral Medicine, AvanceMed—Independent Research Group in Internal Medicine, Cartagena, Colombia
    </addr-line> 
   </aff> 
   <pub-date pub-type="epub">
    <day>
     03
    </day> 
    <month>
     03
    </month>
    <year>
     2025
    </year>
   </pub-date> 
   <volume>
    13
   </volume> 
   <issue>
    03
   </issue>
   <fpage>
    229
   </fpage>
   <lpage>
    242
   </lpage>
   <history>
    <date date-type="received">
     <day>
      2,
     </day>
     <month>
      February
     </month>
     <year>
      2025
     </year>
    </date>
    <date date-type="published">
     <day>
      15,
     </day>
     <month>
      February
     </month>
     <year>
      2025
     </year> 
    </date> 
    <date date-type="accepted">
     <day>
      15,
     </day>
     <month>
      March
     </month>
     <year>
      2025
     </year> 
    </date>
   </history>
   <permissions>
    <copyright-statement>
     © Copyright 2014 by authors and Scientific Research Publishing Inc. 
    </copyright-statement>
    <copyright-year>
     2014
    </copyright-year>
    <license>
     <license-p>
      This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
     </license-p>
    </license>
   </permissions>
   <abstract>
    The skin is the most visible organ of the human body and the second largest, surpassed only by the endothelium. Its functions extend beyond aesthetics, as it is considered the primary protective barrier against external agents such as microorganisms, corrosive substances, ultraviolet radiation, and other harmful vectors. It also plays crucial roles in preventing total body water loss and regulating temperature. This physical, immunological, and chemical barrier is essential for homeostasis and overall well-being. Additionally, the skin can serve as an early indicator of underlying neoplasms, being the epicenter of multiple manifestations of paraneoplastic syndromes. These syndromes represent a heterogeneous group of clinical manifestations caused by the release of substances by tumor cells or the body’s immune response to them. Paraneoplastic skin manifestations, such as acanthosis nigricans, Leser-Trélat syndrome, or necrolytic migratory erythema, are examples of how the skin can reflect systemic alterations related to cancer. The importance of the skin in this context lies in its accessibility for clinical evaluation and its ability to provide critical diagnostic clues. An attentive physician can identify cutaneous signs that act as “red flags”, guiding early cancer detection and potentially improving patient prognosis. Therefore, the skin is not only a barrier but also a reflection of internal health, playing a vital role in diagnosing systemic diseases and clinical oncology.
   </abstract>
   <kwd-group> 
    <kwd>
     Paraneoplastic
    </kwd> 
    <kwd>
      Skin
    </kwd> 
    <kwd>
      Neoplasia
    </kwd> 
    <kwd>
      Oncology
    </kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <sec id="s1">
   <title>1. Introduction</title>
   <p>Paraneoplastic syndromes represent a complex group of clinical manifestations associated with hormonal, hematological, neurological, or metabolic disorders resulting from interactions between underlying neoplastic processes and host immune responses <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref>. These alterations are not a direct consequence of tumor invasion or metastasis but rather systemic mechanisms reflecting the presence of malignancy <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-2">
     [2]
    </xref>. Within this group, dermatological manifestations hold a prominent place, often being the first visible signs of underlying cancer <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref>. These skin changes can provide valuable clues for early diagnosis, disease progression assessment, and, in some cases, even prognosis <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref>-<xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref>.</p>
   <p>Over 50 dermatological manifestations associated with malignancies have been documented in the literature, highlighting the importance of clinical recognition of these findings <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.141303-4">
     [4]
    </xref>. These manifestations can arise at various stages of the disease: before cancer diagnosis, during disease progression, or even in advanced stages post-treatment <xref ref-type="bibr" rid="scirp.141303-4">
     [4]
    </xref>. This temporal variability underscores the need for a comprehensive clinical approach that considers these manifestations as potential markers of underlying neoplasms.</p>
   <p>The interest in the relationship between skin diseases and neoplastic processes dates back to the 19th century <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref>. Austrian dermatologist Ferdinand Ritter von Hebra first proposed a possible connection between cutaneous hyperpigmentation and visceral cancers <xref ref-type="bibr" rid="scirp.141303-5">
     [5]
    </xref>. Decades later, in 1900, Dr. Hollander established the relationship between the spontaneous appearance of seborrheic keratosis and visceral cancer, solidifying this condition as a paraneoplastic manifestation <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. In 1976, German-American dermatologist Helene Ollendorff Curth developed a set of diagnostic criteria to determine the association between skin manifestations and internal neoplasms (<xref ref-type="table" rid="table1">
     Table 1
    </xref>) <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref>. These criteria, still widely used for their versatility, include aspects such as the timing of lesion appearance and its correlation with the underlying malignancy. However, they do not cover all possible presentations, emphasizing the need for a high clinical suspicion <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>The skin acts as a mirror of the body’s systemic conditions, and its detailed study can reveal critical clues about underlying diseases (<xref ref-type="fig" rid="fig1">
     Figure 1
    </xref>) <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. Recognizing paraneoplastic dermatological manifestations should prompt a thorough evaluation to identify underlying malignancies, guiding clinicians in implementing a multidisciplinary approach to optimize patient management (<xref ref-type="table" rid="table2">
     Table 2
    </xref>). Ultimately, a correct interpretation of these signals can contribute to early diagnosis, improved prognosis, and enhanced patient quality of life <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-8">
     [8]
    </xref>.</p>
   <table-wrap id="table1">
    <label>
     <xref ref-type="table" rid="table1">
      Table 1
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.141303-"></xref>Table 1. Curth’s criteria or postulates.</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="custom-bottom-td acenter" width="89.40%" colspan="2"><p style="text-align:center">Curth’s Criteria</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="89.40%" colspan="2"><p style="text-align:center">Major Criteria:</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="6.08%"><p style="text-align:center">1.</p></td> 
      <td class="custom-top-td acenter" width="83.32%"><p style="text-align:center">Simultaneous onset of the neoplasm and dermatosis.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="6.08%"><p style="text-align:center">2.</p></td> 
      <td class="custom-bottom-td acenter" width="83.32%"><p style="text-align:center">Parallel development of both conditions.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="89.40%" colspan="2"><p style="text-align:center">Minor Criteria:</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="6.08%"><p style="text-align:center">1.</p></td> 
      <td class="custom-top-td acenter" width="83.32%"><p style="text-align:center">The condition is not recognized as part of a genetic syndrome.</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="6.08%"><p style="text-align:center">2.</p></td> 
      <td class="acenter" width="83.32%"><p style="text-align:center">A specific tumor is associated with a specific dermatosis.</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="6.08%"><p style="text-align:center">3.</p></td> 
      <td class="acenter" width="83.32%"><p style="text-align:center">The presented cutaneous dermatosis is uncommon.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="6.08%"><p style="text-align:center">4.</p></td> 
      <td class="custom-bottom-td acenter" width="83.32%"><p style="text-align:center">There is a statistically significant association between the skin lesions and the type of neoplasm.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="89.40%" colspan="2"><p style="text-align:center">Adapted from: Curth HO. Skin lesions and internal carcinoma. In: Andrade R, editor. Cancer of the skin: biology, diagnosis, management. Philadelphia: Saunders; 1976.</p></td> 
     </tr> 
    </table>
   </table-wrap>
  </sec><sec id="s2">
   <title>2. Epidemiology</title>
   <p>Paraneoplastic syndromes are rare entities, and although exact statistical data are unavailable, they are estimated to occur in approximately 7% to 15% of malignancies <xref ref-type="bibr" rid="scirp.141303-9">
     [9]
    </xref> <xref ref-type="bibr" rid="scirp.141303-10">
     [10]
    </xref>. Their incidence ranges from 1 to 8 cases per 100,000 inhabitants annually, with a global prevalence of around 4 cases per 100,000 inhabitants. These syndromes can occur at any age, with no specific predilection for sex or race <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. They are primarily associated with solid tumors, most commonly lung, breast, and colon cancers, highlighting the importance of timely and accurate diagnosis in these clinical contexts <xref ref-type="bibr" rid="scirp.141303-10">
     [10]
    </xref>.</p>
  </sec><sec id="s3">
   <title>3. Pathophysiology</title>
   <p>Paraneoplastic syndromes arise from the complex interaction between the tumor and the host, unrelated to tumor invasion or metastasis <xref ref-type="bibr" rid="scirp.141303-10">
     [10]
    </xref>. Their pathophysiology involves multiple biological mechanisms, including the release of growth factors, cytokine production, systemic inflammatory responses, and autoimmune reactions <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>.</p>
   <p>One of the primary mechanisms is the release of growth factors and humoral products by tumor cells <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.141303-4">
     [4]
    </xref>. For example, certain tumors secrete hormones or hormone-like peptides, such as ectopic adrenocorticotropic hormone (ACTH) production in small cell lung carcinoma, leading to Cushing’s syndrome <xref ref-type="bibr" rid="scirp.141303-2">
     [2]
    </xref> <xref ref-type="bibr" rid="scirp.141303-4">
     [4]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. Other tumors may release transforming growth factors (TGF), insulin-like growth factor 1 (IGF1), fibroblast growth factor (FGF), and alpha-melanocyte-stimulating hormone (MSHα), which are implicated in cutaneous manifestations like acanthosis nigricans and Leser-Trélat syndrome <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>.</p>
   <p>Cytokines play a crucial role in paraneoplastic skin manifestations by mediating processes such as inflammation, cell proliferation, and tissue remodeling. Molecules like TGF-α and IL-6 stimulate epidermal proliferation and keratinocyte and fibroblast differentiation, contributing to conditions like acanthosis nigricans, while pro-inflammatory cytokines like TNF-α and IL-1 induce chronic inflammation, as seen in Sweet’s syndrome <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. Additionally, factors like vascular endothelial growth factor (VEGF) promote angiogenesis, present in syndromes like Bazex, and others, such as IL-10, modulate immune responses that favor characteristic lesions in paraneoplastic dermatomyositis <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.141303-11">
     [11]
    </xref> <xref ref-type="bibr" rid="scirp.141303-12">
     [12]
    </xref>.</p>
   <p>Finally, autoimmune processes are closely related to paraneoplastic syndromes. Aberrantly expressed proteins by tumor cells, known as onconeural antigens, can trigger a cross-reactive immune response affecting normal tissues <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-12">
     [12]
    </xref> <xref ref-type="bibr" rid="scirp.141303-13">
     [13]
    </xref>.</p>
   <fig id="fig1" position="float">
    <label>Figure 1</label>
    <caption>
     <title>Figure 1. Changes that should alert to possible underlying neoplasms. Source: Prepared with BIOART resources.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/2153066-rId32.jpeg?20250318025017" />
   </fig>
   <table-wrap id="table2">
    <label>
     <xref ref-type="table" rid="table2">
      Table 2
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.141303-"></xref>Table 2. Some of the main paraneoplastic cutaneous manifestations.</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="100.00%" colspan="4"><p style="text-align:center">Paraneoplastic Syndromes Associated with Occult Neoplasms</p></td> 
     </tr> 
     <tr> 
      <td rowspan="2" class="custom-top-td acenter" width="16.67%"><p style="text-align:center">Disorder</p></td> 
      <td rowspan="2" class="custom-top-td acenter" width="28.30%"><p style="text-align:center">Clinical Findings</p></td> 
      <td rowspan="2" class="custom-top-td acenter" width="20.44%"><p style="text-align:center">Main Associated Malignancy</p></td> 
      <td rowspan="2" class="custom-top-td acenter" width="34.59%"><p style="text-align:center">Histologically</p></td> 
     </tr> 
     <tr> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Acanthosis Nigricans</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Symmetric hyperkeratosis, papillomatosis, and hyperpigmentation in anatomical fold areas.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Gastric adenocarcinoma.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Hyperkeratosis, papillomatosis, and thickening of the spinous layer are observed.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Paraneoplastic Acrokeratosis</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Psoriasiform scaling lesions on surfaces, primarily affecting the nasal bridge and auricle.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Squamous cell carcinoma of the aerodigestive tract.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Hyperkeratosis, acanthosis, parakeratosis, vacuolar degeneration of basal cells, and a perivascular lymphocytic infiltrate.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Dermatomyositis</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Violaceous poikiloderma in sun-exposed areas, heliotrope rash, nail fold telangiectasias, Gottron’s papules, proximal muscle weakness.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Lung, ovarian, nasopharyngeal, and gastrointestinal cancers.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Vacuoles in the dermis, epidermal atrophy, interstitial mucin deposits, and a diffuse lymphocytic infiltrate.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Erythema Gyratum Repens</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Annular, erythematous, pruritic, and scaly lesions with a “wood grain” pattern.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Lung, breast, and esophageal cancers.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Moderate hyperkeratosis, parakeratosis, acanthosis, and spongiosis are observed, along with a mononuclear perivascular inflammatory infiltrate in the dermis</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="16.67%"><p style="text-align:center">NecrolyticMigratory Erythema</p></td> 
      <td class="custom-bottom-td acenter" width="28.30%"><p style="text-align:center">Vesicular, bullous, or superficial erosive skin lesions.</p></td> 
      <td class="custom-bottom-td acenter" width="20.44%"><p style="text-align:center">Pancreatic neuroendocrine tumors [Glucagonoma].</p></td> 
      <td class="custom-bottom-td acenter" width="34.59%"><p style="text-align:center">Edema, epidermal hyperplasia, perivascular inflammation with lymphocytic infiltrate, parakeratosis, and necrosis.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Scleredema</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Induration of cervicofacial skin, trunk, or upper extremities, with progressive nature.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Multiple myeloma, lymphomas.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Dermis with mucin and collagen deposits, without an increase in fibroblast numbers.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Acquired Hypertrichosis Lanuginosa</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Appearance of unpigmented, fine, long, and easily detachable lanugo-type hair.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Lung, breast, and colorectal cancers.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Hair grows horizontally or parallel to the epidermis.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Leser-Trélat Sign</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Sudden onset of diffuse seborrheic keratosis.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Colorectal, gastric, and breast cancers; less commonly, hematologic neoplasms.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">The keratoses present hyperkeratosis, acanthosis, and papillomatosis, with basaloid and squamous cells, horn cysts, and melanocytic pigmentation.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="16.67%"><p style="text-align:center">Paraneoplastic Pemphigus</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="28.30%"><p style="text-align:center">Mucosal erosions with associated stomatitis or vesicles.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.44%"><p style="text-align:center">Non-Hodgkin lymphoma, leukemias, Castleman disease.</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="34.59%"><p style="text-align:center">Intraepithelial acantholysis with a band-like lymphohistiocytic infiltrate is observed</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="16.67%"><p style="text-align:center">Pityriasis Rotunda</p></td> 
      <td class="custom-top-td acenter" width="28.30%"><p style="text-align:center">Circular scaly patches on the torso and proximal regions of the extremities.</p></td> 
      <td class="custom-top-td acenter" width="20.44%"><p style="text-align:center">Hepatocellular carcinoma, prolactinoma.</p></td> 
      <td class="custom-top-td acenter" width="34.59%"><p style="text-align:center">Uniform basal layer pigmentation, orthokeratotic hyperkeratosis, focal agranulosis, or hypogranulosis in the affected area.</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="16.67%"><p style="text-align:center">Sweet’s Syndrome</p></td> 
      <td class="custom-top-td acenter" width="28.30%"><p style="text-align:center">Appearance of erythematous or violaceous plaques and nodules on the skin, accompanied by fever and general malaise.</p></td> 
      <td class="custom-top-td acenter" width="20.44%"><p style="text-align:center">Hematologic neoplasms.</p></td> 
      <td class="custom-top-td acenter" width="34.59%"><p style="text-align:center">Dense, mature neutrophilic infiltrate is found in the mid-dermis, associated with variable degrees of edema, and absence of leukocytoclastic vasculitis</p></td> 
     </tr> 
    </table>
   </table-wrap>
  </sec><sec id="s4">
   <title>4. Acanthosis Nigricans</title>
   <p>Acanthosis nigricans is a cutaneous manifestation classified into two main forms: benign, which accounts for 80% of cases and is closely associated with insulin resistance and obesity, and malignant, a less common but clinically significant variant <xref ref-type="bibr" rid="scirp.141303-14">
     [14]
    </xref>.</p>
   <p>Malignant acanthosis nigricans was the first dermatosis described with a clear relationship to underlying malignancies <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. It affects men and women equally, with no known racial or hereditary predisposition <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. Its onset is usually sudden, with extensive, severe, and rapidly progressive skin involvement <xref ref-type="bibr" rid="scirp.141303-14">
     [14]
    </xref> <xref ref-type="bibr" rid="scirp.141303-15">
     [15]
    </xref>. Clinically, it is characterized by symmetric hyperpigmentation in areas such as the axillae, neck, submammary, inguinal, and cubital fossae, potentially extending to other body parts <xref ref-type="bibr" rid="scirp.141303-16">
     [16]
    </xref>. Lesions often present with skin tags and hyperkeratotic plaques and may be accompanied by pruritus. In advanced cases, it can affect the palms, a condition known as acanthosis palmaris, manifested by darkened, hardened, and rough palms <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-14">
     [14]
    </xref> <xref ref-type="bibr" rid="scirp.141303-16">
     [16]
    </xref>.</p>
   <p>Histologically, hyperkeratosis, papillomatosis, and thickening of the spinous layer are observed. Interestingly, the characteristic hyperpigmentation is not due to melanin deposits but is related to hyperkeratotic changes <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>This condition can appear simultaneously with or precede the diagnosis of an underlying neoplasm. An association of up to 90% with intra-abdominal tumors has been identified, with gastric adenocarcinomas being the most common, representing 70% to 90% of cases <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-16">
     [16]
    </xref>. Less commonly, it is associated with cancers of the pancreas, liver, intestine, ovary, kidney, breast, thyroid, and gallbladder, as well as hematologic neoplasms in rare cases <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-16">
     [16]
    </xref>.</p>
  </sec><sec id="s5">
   <title>5. Paraneoplastic Acrokeratosis</title>
   <p>Acrokeratosis paraneoplastica, or Bazex syndrome, was first described in 1965 by French dermatologist André Bazex and colleagues as a clinical marker of malignancy <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. This syndrome is a rare dermatosis characterized by specific skin lesions frequently associated with malignant tumors, especially of the upper aerodigestive tract <xref ref-type="bibr" rid="scirp.141303-17">
     [17]
    </xref>. Bazex proposed a classification into three clinical stages, reflecting disease progression:</p>
   <p>Histological features include hyperkeratosis, acanthosis, parakeratosis, vacuolar degeneration of basal cells, and a perivascular lymphocytic infiltrate. These characteristics are useful for confirming the diagnosis when clinical suspicion exists <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-18">
     [18]
    </xref>.</p>
   <p>Skin lesions may precede the diagnosis of an underlying neoplasm by 2 to 12 months, making Bazex syndrome a valuable early marker of malignancy <xref ref-type="bibr" rid="scirp.141303-19">
     [19]
    </xref>. Approximately 80% of cases are associated with tumors of the upper aerodigestive tract, such as those affecting the oral cavity, larynx, pharynx, trachea, esophagus, and lungs <xref ref-type="bibr" rid="scirp.141303-17">
     [17]
    </xref> <xref ref-type="bibr" rid="scirp.141303-18">
     [18]
    </xref>. Among these, squamous cell carcinoma is the most frequently related type <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-17">
     [17]
    </xref>.</p>
  </sec><sec id="s6">
   <title>6. Dermatomyositis</title>
   <p>Dermatomyositis is a complex clinical condition characterized by proximal muscle weakness associated with inflammatory myopathy, predominantly in the extensors, along with violaceous poikiloderma in sun-exposed areas. Other findings include nail bed alterations and heliotrope rash, considered its most distinctive semiological sign <xref ref-type="bibr" rid="scirp.141303-12">
     [12]
    </xref>.</p>
   <p>The link between dermatomyositis and malignancy was first described in 1916 by Dr. Stretz, who identified this association in a patient with gastric carcinoma <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. Since then, this relationship has been consolidated, especially in populations from Northern Europe and East Asia <xref ref-type="bibr" rid="scirp.141303-20">
     [20]
    </xref>.</p>
   <p>Clinical indicators suggesting malignancy in the context of dermatomyositis include rapid disease progression, cutaneous necrosis, absence of Raynaud’s phenomenon, and elevated erythrocyte sedimentation rate <xref ref-type="bibr" rid="scirp.141303-20">
     [20]
    </xref> <xref ref-type="bibr" rid="scirp.141303-21">
     [21]
    </xref>.</p>
   <p>Histologically, vacuoles in the dermis, epidermal atrophy, interstitial mucin deposits, and a diffuse lymphocytic infiltrate are observed. In muscle biopsy, findings include type II fiber atrophy, necrosis, hypertrophy, regeneration, and centralization of nuclei in the sarcolemma <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>Although dermatomyositis shows a strong association with adenocarcinomas, a thorough search for possible etiologies is recommended for adequate management <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-20">
     [20]
    </xref> <xref ref-type="bibr" rid="scirp.141303-21">
     [21]
    </xref>.</p>
  </sec><sec id="s7">
   <title>7. Erythema Gyratum Repens</title>
   <p>Erythema gyratum repens is an atypical paraneoplastic dermatosis considered highly specific for underlying malignancies <xref ref-type="bibr" rid="scirp.141303-22">
     [22]
    </xref>. It was first described in 1952 by Dr. Gammel, who reported undulating erythematous lesions with marginal scaling in a patient later diagnosed with breast adenocarcinoma <xref ref-type="bibr" rid="scirp.141303-23">
     [23]
    </xref>.</p>
   <p>Lesions present a “wood grain” or “cypress” pattern, are annular, erythematous, pruritic, and scaly, with rapid progression of up to one centimeter per day <xref ref-type="bibr" rid="scirp.141303-22">
     [22]
    </xref>-<xref ref-type="bibr" rid="scirp.141303-24">
     [24]
    </xref>.</p>
   <p>Histologically, moderate hyperkeratosis, parakeratosis, acanthosis, and spongiosis are observed, along with a mononuclear perivascular inflammatory infiltrate in the dermis <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>Erythema gyratum repens are present in 82% to 84% of cases of underlying malignancy, most frequently in lung cancer, followed by esophageal and breast cancer. Exceptionally, it has been associated with multiple myeloma, as reported in the literature <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-22">
     [22]
    </xref>-<xref ref-type="bibr" rid="scirp.141303-24">
     [24]
    </xref>.</p>
  </sec><sec id="s8">
   <title>8. Necrolytic Migratory Erythema</title>
   <p>Necrolytic migratory erythema is a paraneoplastic dermatosis common in individuals over 45 years old, with a peak incidence in the sixth decade of life <xref ref-type="bibr" rid="scirp.141303-25">
     [25]
    </xref>. It was first described by Becker and colleagues in 1942 <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. Clinically, it is characterized by scaly, erythematous, irregular patches with centrifugal growth, accompanied by superficial erosions and vesiculobullous lesions <xref ref-type="bibr" rid="scirp.141303-25">
     [25]
    </xref> <xref ref-type="bibr" rid="scirp.141303-26">
     [26]
    </xref>. The most affected areas include the perineum, distal extremities, lower abdomen, and face <xref ref-type="bibr" rid="scirp.141303-26">
     [26]
    </xref>.</p>
   <p>Systemic manifestations include hyperglycemia, weight loss, diarrhea, abdominal pain, and neuropsychiatric symptoms. Additionally, there is an increased risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, with an incidence of 24% <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref>. Frequent infections, mainly by Candida albicans and Staphylococcus aureus, can complicate the diagnosis by mimicking chronic infectious processes <xref ref-type="bibr" rid="scirp.141303-27">
     [27]
    </xref>.</p>
   <p>Histologically, findings include edema, epidermal hyperplasia, perivascular inflammation with lymphocytic infiltrate, parakeratosis, and necrosis <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>Necrolytic migratory erythema is closely related to pancreatic neuroendocrine tumors, especially glucagonoma, present in 70% of cases. Its identification is crucial as an early marker, as treatment of the underlying neoplasm results in rapid resolution of skin manifestations <xref ref-type="bibr" rid="scirp.141303-25">
     [25]
    </xref>-<xref ref-type="bibr" rid="scirp.141303-27">
     [27]
    </xref>.</p>
  </sec><sec id="s9">
   <title>9. Scleredema</title>
   <p>Scleredema is an uncommon dermatosis, primarily associated with metabolic conditions such as diabetes mellitus. However, its occurrence as a paraneoplastic dermatosis in the context of lymphomas and multiple myeloma has been documented <xref ref-type="bibr" rid="scirp.141303-28">
     [28]
    </xref>. It was first described in 1752 by Curzio, and in 1902, Buschke consolidated the condition by describing progressive hardening of the neck skin in a patient who had presented with a flu-like illness <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>.</p>
   <p>Clinically, it is characterized by indurated edema in the neck and dorsal region, which can progress to sclerosis and involve larger body areas. Three main variants are recognized:</p>
   <p>Indeterminate description: Progressive presentation without an identifiable underlying disease.</p>
   <p>Differential diagnoses include scleromyxedema and scleroderma. Histologically, an expanded dermis with mucin and collagen deposits is observed, without an increase in fibroblast numbers, helping to differentiate it from other pathologies. It may be associated with systemic involvement, affecting the liver, heart, eyes, and bones <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-28">
     [28]
    </xref>.</p>
   <p>Treatment focuses on the underlying neoplasm, although systemic interventions may be required in some cases. It is frequently associated with multiple myeloma and lymphomas <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>.</p>
  </sec><sec id="s10">
   <title>10. Acquired Hypertrichosis Lanuginosa</title>
   <p>Acquired hypertrichosis lanuginosa was described as a paraneoplastic dermatosis by Turner in 1865, in a patient with breast cancer who developed thick, short, soft, and white hair <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. Since then, reports have been scarce but consistently associated with a poor prognosis. Most cases have been recorded in women <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref>.</p>
   <p>Clinically, it is characterized by the appearance of thin, white, and soft hair, similar to lanugo, predominantly on the face and with a craniocaudal distribution. Trichomegaly is another frequent manifestation <xref ref-type="bibr" rid="scirp.141303-29">
     [29]
    </xref>. The gradual onset of this condition usually precedes the diagnosis of the underlying neoplasm by 2.5 to 3 years, delaying its identification <xref ref-type="bibr" rid="scirp.141303-30">
     [30]
    </xref>. Other manifestations include weight loss, diarrhea, and lymphadenopathy <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref>.</p>
   <p>Histologically, the hair grows horizontally or parallel to the epidermis, in contrast to the usual vertical growth. Hair follicles present immature sebaceous ducts <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>It is closely related to lung and colorectal neoplasms, although it has also been described in breast and ovarian cancers <xref ref-type="bibr" rid="scirp.141303-29">
     [29]
    </xref> <xref ref-type="bibr" rid="scirp.141303-30">
     [30]
    </xref>.</p>
  </sec><sec id="s11">
   <title>11. Leser-Trélat Sign</title>
   <p>The Leser-Trélat sign is a paraneoplastic dermatosis characterized by the sudden and progressive appearance of multiple seborrheic keratoses with verrucous features <xref ref-type="bibr" rid="scirp.141303-31">
     [31]
    </xref> <xref ref-type="bibr" rid="scirp.141303-32">
     [32]
    </xref>. These lesions are usually located on the chest and back but may also be found on the neck, axillae, face, and abdomen <xref ref-type="bibr" rid="scirp.141303-33">
     [33]
    </xref>. The lesions are brown or black and tend to respond favorably to treatment of the underlying neoplasm <xref ref-type="bibr" rid="scirp.141303-31">
     [31]
    </xref>.</p>
   <p>It was first described by Hollander in 1900, who named it in honor of Edmund Leser and Ulysses Trélat, who had previously linked cherry angiomas to neoplastic diseases <xref ref-type="bibr" rid="scirp.141303-31">
     [31]
    </xref>.</p>
   <p>Diagnostic criteria, such as those proposed by Fink et al., suggest that the appearance of 20 or more seborrheic keratoses within six months is highly suggestive of this condition <xref ref-type="bibr" rid="scirp.141303-34">
     [34]
    </xref>.</p>
   <p>Histologically, the keratoses present hyperkeratosis, acanthosis, and papillomatosis, with basaloid and squamous cells, horn cysts, and melanocytic pigmentation. These findings do not differ between benign forms and the Leser-Trélat sign <xref ref-type="bibr" rid="scirp.141303-33">
     [33]
    </xref> <xref ref-type="bibr" rid="scirp.141303-35">
     [35]
    </xref>.</p>
   <p>It is mostly associated with adenocarcinomas of gastric, colorectal, breast, or lung origin, although it can also occur in hematologic neoplasms <xref ref-type="bibr" rid="scirp.141303-31">
     [31]
    </xref>.</p>
  </sec><sec id="s12">
   <title>12. Paraneoplastic Pemphigus</title>
   <p>Paraneoplastic pemphigus was established as a clinical entity in 1990 by Anhalt et al. It shows no significant differences between sexes, and it is estimated that two-thirds of patients have a recognized neoplasm at the onset of the disease <xref ref-type="bibr" rid="scirp.141303-36">
     [36]
    </xref>.</p>
   <p>Among the main clinical manifestations, the most frequent and disabling is persistent stomatitis, often associated with glossitis <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>. There may also be involvement of the oropharynx, nasopharynx, esophagus, and anogenital region <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. Up to 70% of patients may present ocular involvement. As the disease progresses, lesions extend to the head, trunk, and upper extremities, characterized by erythema, blisters, and plaques <xref ref-type="bibr" rid="scirp.141303-37">
     [37]
    </xref> <xref ref-type="bibr" rid="scirp.141303-38">
     [38]
    </xref>.</p>
   <p>Diagnostic criteria proposed by Helm and Camisa include:</p>
   <p>The diagnosis requires the presence of three major criteria or two major and one minor criterion <xref ref-type="bibr" rid="scirp.141303-38">
     [38]
    </xref>.</p>
   <p>Histologically, intraepithelial acantholysis with a band-like lymphohistiocytic infiltrate is observed <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>. On direct immunofluorescence, deposits of IgA, IgG, and C3 are found. Additionally, autoantibodies against desmoglein 3 and, less frequently, against periplakin, envoplakin, desmoplakins I and II, and A2ML1 have been identified <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-3">
     [3]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref>.</p>
   <p>Paraneoplastic pemphigus, which usually present between the fifth and eighth decades of life, is associated in 80% of cases with hematologic neoplasms such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Castleman disease. It may also be related to solid tumors like lung, colon, or stomach cancer <xref ref-type="bibr" rid="scirp.141303-36">
     [36]
    </xref>-<xref ref-type="bibr" rid="scirp.141303-38">
     [38]
    </xref>.</p>
  </sec><sec id="s13">
   <title>13. Pityriasis Rotunda</title>
   <p>Pityriasis rotunda is a rare dermatosis characterized by alterations in keratinization, with oval, scaly plaques with well-defined borders, which may be hypo- or hyperpigmented compared to the surrounding skin. The lesions, usually located on the trunk, are multiple, may coalesce, and show no inflammation or pruritus <xref ref-type="bibr" rid="scirp.141303-39">
     [39]
    </xref>.</p>
   <p>First described by Dr. Toyama in 1906 in Japanese patients, it is classified into:</p>
   <p>Histologically, uniform basal layer pigmentation, orthokeratotic hyperkeratosis, focal agranulosis, or hypogranulosis in the affected area may be found <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>Although it can occur in the presence of non-neoplastic diseases such as tuberculosis, leprosy, or hepatic or pulmonary diseases, it has been described in association with solid tumors, especially hepatocellular, gastric, esophageal, and prostate carcinomas, as well as multiple myeloma and chronic lymphocytic leukemia <xref ref-type="bibr" rid="scirp.141303-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref> <xref ref-type="bibr" rid="scirp.141303-39">
     [39]
    </xref>.</p>
  </sec><sec id="s14">
   <title>14. Sweet’s Syndrome</title>
   <p>Sweet’s syndrome was first described in 1964 by Dr. Robert Douglas Sweet as an “acute febrile neutrophilic dermatosis”. It is the most frequent neutrophilic dermatosis, characterized by neutrophilic infiltrate, fever, and painful skin lesions such as papules, nodules, or erythematous plaques <xref ref-type="bibr" rid="scirp.141303-40">
     [40]
    </xref> <xref ref-type="bibr" rid="scirp.141303-41">
     [41]
    </xref>.</p>
   <p>This dermatosis has three types of presentation: classic or idiopathic, malignancy-associated, and drug-induced. Additionally, major and minor diagnostic criteria have been established, requiring the presence of 2 major and at least 2 minor criteria for diagnosis <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-40">
     [40]
    </xref> <xref ref-type="bibr" rid="scirp.141303-41">
     [41]
    </xref>.</p>
   <p>Histologically, a dense, mature neutrophilic infiltrate is found in the mid-dermis, associated with variable degrees of edema, and absence of leukocytoclastic vasculitis <xref ref-type="bibr" rid="scirp.141303-7">
     [7]
    </xref>.</p>
   <p>It is estimated that around 25% of patients with Sweet’s syndrome have an underlying neoplasm, usually hematologic, with acute myeloid leukemia being the most frequent in up to 42% of cases, while association with solid tumors is rare <xref ref-type="bibr" rid="scirp.141303-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.141303-40">
     [40]
    </xref> <xref ref-type="bibr" rid="scirp.141303-41">
     [41]
    </xref>.</p>
  </sec><sec id="s15">
   <title>15. Conclusion</title>
   <p>Paraneoplastic cutaneous syndromes represent highly relevant clinical manifestations in medical practice, as they can serve as early signals of an underlying neoplasm. Recognizing the clinical and semiological features of these skin alterations is essential for identifying specific patterns that guide accurate diagnosis. Early detection of these syndromes not only allows for timely intervention but also significantly improves patient prognosis by facilitating early management of the underlying disease. Therefore, it is imperative to strengthen medical training in this area and promote clinical research to expand knowledge about these complex interactions between the skin and neoplasms.</p>
  </sec><sec id="s16">
   <title>Funding</title>
   <p>The study was funded with personal resources.</p>
  </sec>
 </body><back>
  <ref-list>
   <title>References</title>
   <ref id="scirp.141303-ref1">
    <label>1</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Silva, J.A.D., Mesquita, K.D.C., Igreja, A.C.D.S.M., Lucas, I.C.R.N., Freitas, A.F., Oliveira, S.M.D., et al. (2013) Paraneoplastic Cutaneous Manifestations: Concepts and Updates. Anais Brasileiros de Dermatologia, 88, 9-22. &gt;https://doi.org/10.1590/s0365-05962013000100001
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref2">
    <label>2</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Pelosof, L.C. and Gerber, D.E. (2010) Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. Mayo Clinic Proceedings, 85, 838-854. &gt;https://doi.org/10.4065/mcp.2010.0099
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref3">
    <label>3</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Henry, K. (2019) Paraneoplastic Syndromes: Definitions, Classification, Pathophysiology and Principles of Treatment. Seminars in Diagnostic Pathology, 36, 204-210. &gt;https://doi.org/10.1053/j.semdp.2019.01.002
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref4">
    <label>4</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Badawy, M., Revzin, M.V., Consul, N., Soliman, M., Ganeshan, D.M., Heymann, J.C., et al. (2023) Paraneoplastic Syndromes from Head to Toe: Pathophysiology, Imaging Features, and Workup. RadioGraphics, 43, 1-18. &gt;https://doi.org/10.1148/rg.220085
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref5">
    <label>5</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Aniyathodiyil, P.U. (2020) Von Hebra—Legend in dermatology. Journal of Skin and Sexually Transmitted Diseases, 2, 35-36. &gt;https://doi.org/10.25259/jsstd_41_2019
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref6">
    <label>6</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Alter, M., Mengoni, M. and Gaffal, E. (2020) Cutaneous Manifestations of Internal Malignancy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 18, 456-469. &gt;https://doi.org/10.1111/ddg.14093
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref7">
    <label>7</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Pipkin, C.A. and Lio, P.A. (2008) Cutaneous Manifestations of Internal Malignancies: An Overview. Dermatologic Clinics, 26, 1-15. &gt;https://doi.org/10.1016/j.det.2007.08.002
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref8">
    <label>8</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Yuste-Chaves, M. and Unamuno-Pérez, P. (2013) Cutaneous Alerts in Systemic Malignancy: Part I. Actas Dermo-Sifiliográficas (English Edition), 104, 285-298. &gt;https://doi.org/10.1016/j.adengl.2012.03.027
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref9">
    <label>9</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Al-Showbaki, L., Toubasi, A.A., Jaber, D.Z., Shdifat, M.A., Al-Maani, N., Qudah, O., et al. (2024) Paraneoplastic Cutaneous Manifestations of Hepatocellular Carcinoma. a Systematic Review and Meta-analysis. Journal of Cancer, 15, 1021-1029. &gt;https://doi.org/10.7150/jca.88931
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref10">
    <label>10</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Vogrig, A., Gigli, G.L., Segatti, S., Corazza, E., Marini, A., Bernardini, A., et al. (2019) Epidemiology of Paraneoplastic Neurological Syndromes: A Population-Based Study. Journal of Neurology, 267, 26-35. &gt;https://doi.org/10.1007/s00415-019-09544-1
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref11">
    <label>11</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ionescu, V.A., Gheorghe, G., Georgescu, T.F., Buica, V., Catanescu, M., Cercel, I., et al. (2025) Cutaneous Paraneoplastic Syndromes in Colorectal Cancer Patients. Gastrointestinal Disorders, 7, Article 8. &gt;https://doi.org/10.3390/gidisord7010008
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref12">
    <label>12</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Didona, D., Fania, L., Didona, B., Eming, R., Hertl, M. and Di Zenzo, G. (2020) Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis. International Journal of Molecular Sciences, 21, Article 2178. &gt;https://doi.org/10.3390/ijms21062178
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref13">
    <label>13</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     McCormick, B.J., Zieman, D., Sluzevich, J.C. and Alhaj Moustafa, M. (2024) Clinical Features of Cutaneous Paraneoplastic Syndromes in Hodgkin Lymphoma. Journal of Investigative Medicine High Impact Case Reports, 12, 1-5. &gt;https://doi.org/10.1177/23247096241255840
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref14">
    <label>14</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     González, L. and Peñaranda, E. (2010) Acantosis nigricans: Dos presentaciones de una misma enfermedad. &gt;https://revista.asocolderma.org.co/index.php/asocolderma/article/view/344 
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref15">
    <label>15</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Carreño-Fernandez, A.V. and Avella-Chaparro, D.A. (2021) Prevalencia de Acantosis Nigricans y factores asociados a Síndrome Metabólico en Nobsa-Boyacá. Revista Investigación en Salud Universidad de Boyacá, 8, 63-74. &gt;https://doi.org/10.24267/23897325.625
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref16">
    <label>16</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Das, A., Datta, D., Kassir, M., Wollina, U., Galadari, H., Lotti, T., et al. (2020) Acanthosis Nigricans: A Review. Journal of Cosmetic Dermatology, 19, 1857-1865. &gt;https://doi.org/10.1111/jocd.13544
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref17">
    <label>17</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Räßler, F., Goetze, S. and Elsner, P. (2017) Acrokeratosis Paraneoplastica (Bazex Syndrome)—A Systematic Review on Risk Factors, Diagnosis, Prognosis and Management. Journal of the European Academy of Dermatology and Venereology, 31, 1119-1136. &gt;https://doi.org/10.1111/jdv.14199
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref18">
    <label>18</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Yamada, A., Umemoto, N., Demitsu, T. and Kitamura, O. (2024) Acrokeratosis Neoplastica (Bazex Syndrome): Report of Two Cases and Literature Review. Heliyon, 10, e26411. &gt;https://doi.org/10.1016/j.heliyon.2024.e26411
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref19">
    <label>19</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Couselo-Rodríguez, C., Galego-Fernández, R. and Núñez-Fernández, M.J. (2024) Síndrome de Bazex con resolución completa tras tratamiento quirúrgico de carcinoma epidermoide de laringe. Actas Dermo-Sifiliográficas, 115, 86. &gt;https://doi.org/10.1016/j.ad.2022.08.035
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref20">
    <label>20</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Cassard, L., Seraly, N., Riegert, M., Patel, A. and Fernandez, A. (2024) Dermatomyositis: Practical Guidance and Unmet Needs. ImmunoTargets and Therapy, 13, 151-172. &gt;https://doi.org/10.2147/itt.s381472
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref21">
    <label>21</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Julita K Putri, W. (2023) Dermatomyositis: A Review of Diagnosis and Classification Criteria. International Journal of Science and Healthcare Research, 8, 42-48. &gt;https://doi.org/10.52403/ijshr.20230407
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref22">
    <label>22</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Gore, M. and Winters, M. (2011) Erythema Gyratum Repens: A Rare Paraneoplastic Rash. Western Journal of Emergency Medicine, 12, 556-558. &gt;https://doi.org/10.5811/westjem.2010.11.2090
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref23">
    <label>23</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Votquenne, N. and Richert, B. (2020) Erythema Gyratum Repens. JAMA Dermatology, 156, 912. &gt;https://doi.org/10.1001/jamadermatol.2020.1694
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref24">
    <label>24</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Malek, A., Nasnas, P. and Nasnas, R. (2017) Erythema Gyratum Repens Secondary to Acute Myeloblastic Leukemia. Journal of Clinical &amp; Experimental Dermatology Research, 8, Article ID: 1000406. &gt;https://doi.org/10.4172/2155-9554.1000406
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref25">
    <label>25</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Qadan, M., Visser, B., Kim, J., Pai, R. and Triadafilopoulos, G. (2011) Abdominal Mass, Anemia, Diabetes Mellitus, and Necrolytic Migratory Erythema. Digestive Diseases and Sciences, 57, 1465-1468. &gt;https://doi.org/10.1007/s10620-011-1967-5
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref26">
    <label>26</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Wu, S., Bai, J., Xu, J., Ma, Q. and Wu, Z. (2014) Necrolytic Migratory Erythema as the First Manifestation of Pancreatic Neuroendocrine Tumor. World Journal of Surgical Oncology, 12, Article No. 220. &gt;https://doi.org/10.1186/1477-7819-12-220
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref27">
    <label>27</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Rodríguez, G., Vargas, E., Abaúnza, C. and Cáceres, S. (2016) Eritema necrolítico migratorio y glucagonoma pancreático. Biomédica, 36, 176-181. &gt;https://doi.org/10.7705/biomedica.v36i3.2723
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref28">
    <label>28</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Hernaiz Calvo, L.M., Abadías Granado, I., Sánchez Bernal, J., Abecia Martínez, E.I. and Gilaberte Calzada, Y. (2021) Escleredema: mÁs allá del endurecimiento de la piel. Medicina de Familia. Semergen, 47, 501-503. &gt;https://doi.org/10.1016/j.semerg.2021.05.002
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref29">
    <label>29</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Gómez-Arias, P.J., Vélez García-Nieto, A.J. and Salido-Vallejo, R. (2021) Paraneoplastic Hypertrichosis Lanuginosa Acquisita. Indian Journal of Dermatology, Venereology and Leprology, 88, 525-526. &gt;https://doi.org/10.25259/ijdvl_448_20
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref30">
    <label>30</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Slee, P.H.T.J., van der Waal, R.I.F., Schagen van Leeuwen, J.H., Tupker, R.A., Timmer, R., Seldenrijk, C.A., et al. (2007) Paraneoplastic Hypertrichosis Lanuginosa Acquisita: Uncommon or Overlooked? British Journal of Dermatology, 157, 1087-1092. &gt;https://doi.org/10.1111/j.1365-2133.2007.08253.x
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref31">
    <label>31</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ortiz-Pérez, D.F., Montoya-Jaramillo, M.E., Emiliani-Cortes, J.D., Flórez-Theran, K.P., Sierra-Tapia, K.A., Hernández-Salgado, M., et al. (2024) Leser-Trélat Associated with Myeloproliferative Neoplasia: When the Skin Speaks. Journal of Biosciences and Medicines, 12, 335-341. &gt;https://doi.org/10.4236/jbm.2024.1212026
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref32">
    <label>32</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Tibaduiza Mogollon, Y.A., Miranda Diaz, A.J. and Navas Torrejano, D.S. (2019) Signo de Leser-Trélat, signo paraneoplásico en cáncer de mama metastásico: Presentación de caso. Revista Med, 26, 60-64. &gt;https://doi.org/10.18359/rmed.3554
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref33">
    <label>33</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Safa, G. and Darrieux, L. (2011) Leser-Trélat Sign without Internal Malignancy. Case Reports in Oncology, 4, 175-177. &gt;https://doi.org/10.1159/000327363
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref34">
    <label>34</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Fink, A., Filz, D., Krajnik, G., Jurecka, W., Ludwig, H. and Steiner, A. (2009) Seborrhoeic Keratoses in Patients with Internal Malignancies: A Case-Control Study with Prospective Accrual of Patients. Journal of the European Academy of Dermatology and Venereology, 23, 1316-1319. &gt;https://doi.org/10.1111/j.1468-3083.2009.03163.x
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref35">
    <label>35</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Schwartz, R.A. (1996) Sign of Leser-Trelat. Journal of the American Academy of Dermatology, 35, 88-95. &gt;https://doi.org/10.1016/s0190-9622(96)90502-2
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref36">
    <label>36</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Tirado-Sánchez, A. and Bonifaz, A. (2017) Paraneoplastic Pemphigus. A Life-Threatening Autoimmune Blistering Disease: A Retrospective Study from a Tertiary Care Center in South India. Actas Dermo-Sifiliográficas, 108, 902-910. &gt;https://doi.org/10.1016/j.ad.2017.04.024
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref37">
    <label>37</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Sathishkumar, D., Agrawal, P., Baitule, A.M., Thomas, M., Eapen, A., Kumar, S., et al. (2021) Paraneoplastic Autoimmune Multiorgan Syndrome. Indian Dermatology Online Journal, 12, 572-576. &gt;https://doi.org/10.4103/idoj.idoj_640_20
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref38">
    <label>38</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Didona, D., Didona, B., Richetta, A.G., Cantisani, C., Moliterni, E., Calvieri, S., et al. (2015) Paraneoplastic Pemphigus: A Trait D’union between Dermatology and Oncology. Advances in Modern Oncology Research, 1, 97-103. &gt;https://doi.org/10.18282/amor.v1.i2.42
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref39">
    <label>39</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Manrique, G., Herrera, L., Bustamante, I. and Ordóñez, M.F. (2017) Pitiriasis rotunda en Colombia. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica, 25, 54-56. &gt;https://doi.org/10.29176/2590843x.322
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref40">
    <label>40</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Andrea Londoño, P., Hernando Moreno, L. and Rueda, R. (2008) Síndrome de Sweet Sweet’ syndrome. &gt;https://revista.asocolderma.org.co/index.php/asocolderma/article/view/160?time=1712825478 
    </mixed-citation>
   </ref>
   <ref id="scirp.141303-ref41">
    <label>41</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Villarreal-Villarreal, C.D., Ocampo-Candiani, J. and Villarreal-Martínez, A. (2016) Sweet Syndrome: A Review and Update. Actas Dermo-Sifiliográficas, 107, 369-378. &gt;https://doi.org/10.1016/j.ad.2015.12.001
    </mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>